X038167c2.c7d9.47a2.9172.1cfe391c8131
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 48
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013514 | — | cohortMD2 | 0.944 |
| 2 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.935 |
| 3 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.921 |
| 4 | C3L-02164 | — | cohortMD2 | 0.915 |
| 5 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.913 |
| 6 | SRR821602 | GTEX | — | 0.913 |
| 7 | SRR1382532 | GTEX | — | 0.908 |
| 8 | SRR33346958 | — | — | 0.906 |
| 9 | TCGA-A2-A0EP-01A-52R-A22U-07 | — | A | 0.905 |
| 10 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.620 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |